There are normally four steps to approve (or not ) a medicine: step 1: it must be proven that this drug is not toxic step 2: it must be proven that this drug is active on sick people step 3: it is compared to other drugs which have the same indication step 4: is the pharmacovigilance. The drug is monitored during all its commercialization.
During the approval of biosimilar agents, step 2 is omitted because we need to establish that there are “no clinically meaningful differences” in the efficacy and safety<span> of the biosimilar when compared to the original, which can be done in step 3.</span>
The very highest level; this is because of the 10% rule in which 10% of the energy in a trophic level directly below one level is present in that level.
it is considered feedback mechanisms because the menstrual cycle only happens when the hormone is released, it causes the target tissues to react, that reaction is the feedback.
